Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
A phase 2 trial of Azacitidine, Romidepsin, Belinostat, Pralatrexate and Gemcitabine in Peripheral T-cell lymphomas, run by University of Virginia, now recruiting.
Overview
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL is a phase 2 interventional study registered as NCT04747236 by University of Virginia, with 50 participants planned, started 2021-02-19 and due to reach its primary completion in 2028-06-02. Interventions recorded: Azacytidine, Romidepsin, Belinostat, Pralatrexate, Gemcitabine. Conditions recorded: PTCL.
Linked to the drug Romidepsin because the registry names it among its interventions and Peripheral T-cell lymphomas among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialTo Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Shares Pralatrexate, Belinostat, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialA Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
Shares Romidepsin and the tag pipeline.
- TrialA Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialMB-105 in Patients With CD5 Positive T-cell Lymphoma
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialDepsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
Shares Romidepsin and the tag pipeline.
- TrialA Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialStudy to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialValemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.